Malignancy rates and comparisons to the general US population through 3 years in guselkumab-treated moderate-to-severe psoriasis patients in VOYAGE 1&2

被引：0
|
作者：
Papp, K. A. [1 ]
Reich, K. [2 ,3 ]
Gordon, K. B. [4 ]
Lebwohl, M. [5 ]
Song, M. [6 ]
Ramachandran, P. [7 ]
Randazzo, B. [6 ]
Shen, Y. -K. [6 ]
Blauvelt, A. [8 ]
机构：
[1] Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[2] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Ctr Translat Res Inflammatory Skin Disorders, Hamburg, Germany
[3] Skinflammat Ctr, Hamburg, Germany
[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Janssen Res & Dev LLC, Horsham, PA USA
[8] Oregon Med Res Ctr, Portland, OR USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [41] Sustained improvement in general health-related quality life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 3-year data from clinical trial VOYAGE 2
    Reich, K.
    Gordon, K. B.
    Foley, P.
    Lomaga, M.
    Han, C.
    Song, M.
    Shen, Y. -K.
    Radtke, M. A.
    Wu, J. J.
    Armstrong, A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB280 - AB280
  • [42] Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study
    Gordon, K. B.
    Armstrong, A. W.
    Han, C.
    Foley, P.
    Song, M.
    Wasfi, Y.
    You, Y.
    Shen, Y. -K.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (11) : 1940 - 1949
  • [43] Low-risk of serious infections and infections of interest in psoriasis patients treated with Guselkumab for 5 years in VOYAGE 1 and 2 phase 3 trials
    Langley, R.
    Thaci, D.
    Blauvelt, A.
    Tsai, T. -F.
    Miller, M.
    Yu, J.
    Shen, Y. -K.
    You, Y.
    Yang, Y. -W.
    Papp, K. A.
    Puig, L.
    Foley, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 35 - 35
  • [44] Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2
    Merola, Joseph F.
    Thaci, Diamant
    Choi, Olivia
    Chan, Daphne
    Yang, Ya-Wen
    Miller, Megan
    You, Yin
    Li, Shu
    Blauvelt, Andrew
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB170 - AB170
  • [45] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    Armstrong, April W.
    Reich, Kristian
    Foley, Peter
    Han, Chenglong
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Papp, Kim A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (01) : 155 - 164
  • [46] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    April W. Armstrong
    Kristian Reich
    Peter Foley
    Chenglong Han
    Michael Song
    Yaung-Kaung Shen
    Yin You
    Kim A. Papp
    American Journal of Clinical Dermatology, 2019, 20 : 155 - 164
  • [47] SPEED OF RESPONSE OF GUSELKUMAB COMPARED WITH ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: RESULTS THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE-BLINDED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALS
    Blauvelt, Andrew
    Tyring, Stephen
    Philipp, Sandra
    Adam, David
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Bagel, Jerry
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 21 - 21
  • [48] Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: Results through week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrea
    Tyring, Stephen
    Philipp, Sandra
    Adam, David
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB267 - AB267
  • [49] Clinician-reported PASI versus patient-reported symptoms and signs in moderate to severe psoriasis patients: Voyage 1&2 clinical trials
    Gordon, K.
    Han, C.
    Li, S.
    You, Y.
    Song, M.
    Fakharzadeh, S.
    Crowley, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 42 - 42
  • [50] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (12) : 1535 - 1545
12345